MME and hydrops fetalis: The use of angiotensin receptor/neprilysin inhibitors (ARNI) is currently recommended for the treatment of heart failure with reduced ejection fraction (HFrEF); in the PARADIGM‐HF trial (McMurray et al., 2014), treatment with sacubitril/valsartan (S/V) was associated with a 20% reduction in the primary composite endpoint of cardiovascular death or HF hospitalization compared with enalapril.